These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18938079)

  • 1. Peptides based on CcdB protein as novel inhibitors of bacterial topoisomerases.
    Trovatti E; Cotrim CA; Garrido SS; Barros RS; Marchetto R
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6161-4. PubMed ID: 18938079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of peptides from bacterial ParE toxin as inhibitors of topoisomerases.
    Barbosa LC; Garrido SS; Garcia A; Delfino DB; Santos Ldo N; Marchetto R
    Eur J Med Chem; 2012 Aug; 54():591-6. PubMed ID: 22749642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of DNA gyrase with the bacterial toxin CcdB: evidence for the existence of two gyrase-CcdB complexes.
    Kampranis SC; Howells AJ; Maxwell A
    J Mol Biol; 1999 Oct; 293(3):733-44. PubMed ID: 10543963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The F plasmid CcdB protein induces efficient ATP-dependent DNA cleavage by gyrase.
    Bernard P; Kézdy KE; Van Melderen L; Steyaert J; Wyns L; Pato ML; Higgins PN; Couturier M
    J Mol Biol; 1993 Dec; 234(3):534-41. PubMed ID: 8254658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of gyrase poisoning by the addiction toxin CcdB.
    Dao-Thi MH; Van Melderen L; De Genst E; Afif H; Buts L; Wyns L; Loris R
    J Mol Biol; 2005 May; 348(5):1091-102. PubMed ID: 15854646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of CcdB, a topoisomerase poison from E. coli.
    Loris R; Dao-Thi MH; Bahassi EM; Van Melderen L; Poortmans F; Liddington R; Couturier M; Wyns L
    J Mol Biol; 1999 Jan; 285(4):1667-77. PubMed ID: 9917404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejuvenation of CcdB-poisoned gyrase by an intrinsically disordered protein domain.
    De Jonge N; Garcia-Pino A; Buts L; Haesaerts S; Charlier D; Zangger K; Wyns L; De Greve H; Loris R
    Mol Cell; 2009 Jul; 35(2):154-63. PubMed ID: 19647513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition.
    Heddle JG; Blance SJ; Zamble DB; Hollfelder F; Miller DA; Wentzell LM; Walsh CT; Maxwell A
    J Mol Biol; 2001 Apr; 307(5):1223-34. PubMed ID: 11292337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partner switching mechanisms in inactivation and rejuvenation of Escherichia coli DNA gyrase by F plasmid proteins LetD (CcdB) and LetA (CcdA).
    Maki S; Takiguchi S; Horiuchi T; Sekimizu K; Miki T
    J Mol Biol; 1996 Mar; 256(3):473-82. PubMed ID: 8604132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of the F plasmid killer protein, CcdB, with DNA gyrase: induction of DNA cleavage and blocking of transcription.
    Critchlow SE; O'Dea MH; Howells AJ; Couturier M; Gellert M; Maxwell A
    J Mol Biol; 1997 Nov; 273(4):826-39. PubMed ID: 9367775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization.
    Hsu YH; Chung MW; Li TK
    Nucleic Acids Res; 2006; 34(10):3128-38. PubMed ID: 16757578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural basis for substrate specificity in DNA topoisomerase IV.
    Corbett KD; Schoeffler AJ; Thomsen ND; Berger JM
    J Mol Biol; 2005 Aug; 351(3):545-61. PubMed ID: 16023670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DNA supercoiling and topoisomerases in Escherichia coli].
    Gómez-Eichelmann MC; Camacho-Carranza R
    Rev Latinoam Microbiol; 1995; 37(3):291-304. PubMed ID: 8850348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis.
    Aubry A; Fisher LM; Jarlier V; Cambau E
    Biochem Biophys Res Commun; 2006 Sep; 348(1):158-65. PubMed ID: 16876125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What makes a type IIA topoisomerase a gyrase or a Topo IV?
    Hirsch J; Klostermeier D
    Nucleic Acids Res; 2021 Jun; 49(11):6027-6042. PubMed ID: 33905522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of CcdB with DNA gyrase. Inactivation of Gyra, poisoning of the gyrase-DNA complex, and the antidote action of CcdA.
    Bahassi EM; O'Dea MH; Allali N; Messens J; Gellert M; Couturier M
    J Biol Chem; 1999 Apr; 274(16):10936-44. PubMed ID: 10196173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular interactions of the CcdB poison with its bacterial target, the DNA gyrase.
    Van Melderen L
    Int J Med Microbiol; 2002 Feb; 291(6-7):537-44. PubMed ID: 11890555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes.
    Bernard P; Couturier M
    J Mol Biol; 1992 Aug; 226(3):735-45. PubMed ID: 1324324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chirality sensing by Escherichia coli topoisomerase IV and the mechanism of type II topoisomerases.
    Stone MD; Bryant Z; Crisona NJ; Smith SB; Vologodskii A; Bustamante C; Cozzarelli NR
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8654-9. PubMed ID: 12857958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Driving forces of gyrase recognition by the addiction toxin CcdB.
    Simic M; De Jonge N; Loris R; Vesnaver G; Lah J
    J Biol Chem; 2009 Jul; 284(30):20002-10. PubMed ID: 19465484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.